Sign in

Private company

Vaccinogen

Logo: vaccinogeninc.com4

American biotechnology company

Vaccinogen Inc. is a US biotechnology company based in Baltimore. It is currently developing a potential cancer immunotherapy called OncoVAX, where a patient's own tumor cells are used as the vaccine, adjuvanted by BCG. This product was evaluated in Phase III in colon cancer in the 1990s and another Phase III study, called ACTIVE, is currently recruiting stage II colon cancer patients.3 Wikipedia text CC BY-SA 4.0

Last updated Oct 21, 2026.

Overview

2007Founded1
  • Industrybiotechnology1
  • HeadquartersBaltimore1
  • Websitewww.vaccinogeninc.com
  • Legal formpublic company1
  • Incorporated inMD5
  • Business address949 Fell Street, Baltimore, Md 212315
  • Filer categorySmaller reporting company5

See how the biggest companies compare on our leaderboards

Vaccinogen image from its website
Image: vaccinogeninc.com7

Vaccinogen Inc. is a US biotechnology company based in Baltimore. It is currently developing a potential cancer immunotherapy called OncoVAX, where a patient's own tumor cells are used as the vaccine, adjuvanted by BCG. This product was evaluated in Phase III in colon cancer in the 1990s and another Phase III study, called ACTIVE, is currently recruiting stage II colon cancer patients. Vaccinogen calls its approach 'Active Specific Immunotherapy' or ASI.3

What it owns

What Vaccinogen reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.1M8 Dec 31, 2014$941.6K8 Dec 31, 2013+22.1%
Accumulated depreciation$756.7K8 Dec 31, 2014$742.8K8 Dec 31, 2013+1.9%
Property and equipment, net$393.0K8 Dec 31, 2014$198.8K8 Dec 31, 2013+97.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$3.0M8 Dec 31, 2014$73.1K8 Dec 31, 2013+4060.2%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$56.0M8 Dec 31, 2014$62.7M8 Dec 31, 2013−10.7%
Finite-lived intangibles, gross$84.6M8 Dec 31, 2014$84.6M8 Dec 31, 20130%
Accumulated amortization$28.6M8 Dec 31, 2014$21.9M8 Dec 31, 2013+30.6%
Finite-lived intangibles, net$56.0M8 Dec 31, 2014$62.7M9 Dec 31, 2013−10.7%

Inventory

ItemLatestA year beforeChange
Inventory, total$99.2K8 Dec 31, 2014$100.2K8 Dec 31, 2013−0.9%

The story

Vaccinogen originated in work done by the company's founder, Dr Michael Hanna, in the late 1970s and early 1980s when he was Director of the National Cancer Institute's Frederick Cancer Research Center in Frederick, Maryland. Hanna founded a company to develop what became OncoVAX and this was acquired by a company from Seattle called Intracel, but that company filed for bankruptcy in 2001. Vaccinogen was formed in 2007 to pick up the intellectual property and other assets from Intracel. Dr Ben Carson was chairman of the company from August 2014 until the announcement of his US presidential bid in May 2015. Carson had previously served on Vaccinogen's Medical Advisory Board.

From Wikipedia’s article on Vaccinogen, shared under CC BY-SA 4.0.6

Leadership

Who has led Vaccinogen, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael G. Hanna Jr.2013–2015

Chair

  1. Michael G. Hanna Jr.2013–2015

President

  1. Andrew Tussing2013

Chief operating officer

  1. Andrew Tussing2013
2010201520202025
Board members and other officers (10)

Products and brands

OncoVAX manufacturing

OncoVAX employs a 'centralised' manufacturing process where the patient's tumour sample is shipped to a company-owned cGMP manufacturing facility in the Dutch town of Emmen for processing and then shipped back to the hospital for administration to the patient. In the 8701 study manufacturing was not carried out under cGMP conditions. Subsequent to 8701 a small 15-patient study was carried out with manufacturing taking place under cGMP (ClinicalTrials.gov identifier NCT00016133). This study found that the immunogenicity of OncoVAX was unaffected by the manufacturing process.

Location

Vaccinogen is headquartered in Baltimore at 949 Fell Street near Fell's Point. The company moved there in February 2015 after previously having been located at Frederick, Maryland. The company also maintains laboratories in Dublin and its manufacturing facility at Emmen. The Emmen location of Vaccinogen B.V. was declared bankrupt in 2017.

From Wikipedia’s article on Vaccinogen, shared under CC BY-SA 4.0.6

Timeline

  1. Sep 3, 2013New chief executive Michael G. Hanna Jr. becomes CEO10
  2. 2007Founded Founded1

SEC filer profile

How Vaccinogen is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARVACCINOGEN INC2
  • CIK0001453001
  • Filer statusSmaller reporting company2
  • Incorporated inMaryland2
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address949 Fell Street, Baltimore, MD 212312
  • Phone410-387-40002
  • Shares outstanding37,321,078 as of Nov 6, 201521
  • Public float$46.9M as of Jun 30, 20148
  • On EDGAR sinceDec 23, 20082
  • Filings125 in all: 8-K (26), 4 (17), 3 (12), D (8), 10-Q (7), CORRESP (6), SC 13G (6), UPLOAD (5)2
    All 32 form types

    D/A (4), 10-12G/A (3), SC 13D (3), 10-K (2), 144 (2), 3/A (2), 424B3 (2), EFFECT (2), NT 10-K (2), SC 13G/A (2), 1-A (1), 10-12G (1), 10-K/A (1), 10-Q/A (1), 8-K/A (1), NT 10-Q (1), POS AM (1), REGDEX (1), REVOKED (1), S-1 (1), S-1/A (1), S-8 (1), SC 13D/A (1), WDL-REQ (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2015
    Quarterly report (10-Q) Nov 16, 2015
    Latest 8-K (8-K) Jul 1, 2016

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
    Company websiteVaccinogen logo
  5. 5
  6. 6
  7. 7
    Company websiteVaccinogen photo
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21